Search the GHTC website

Global health R&D delivers for Massachusetts

US government investment in global health R&D has delivered

Amount
$731.1 million
to Massachusetts research institutions
Jobs
8,400+ new jobs
for Massachusetts
Massachusetts's top USG-funded global health R&D institutions

Massachusetts's top USG-funded global health R&D institutions

Harvard University (including School of Public Health, Public Health AIDS Initiative, and Harvard Medical School)
$135 million
Massachusetts General Hospital (including CAMtech and Center for Integration of Medicine & Innovative Technology)
$93.4 million
Beth Israel Deaconess Medical Center
$89.8 million
Brigham and Women's Hospital
$82.3 million
University of Massachusetts Medical School
$80.4 million
Broad Institute
$44.1 million
Tufts University (including Tufts Medical Center)
$34.4 million
Dana-Farber Cancer Institute
$32 million
Boston University (including Boston University Medical Campus and Center for Global Health and Development)
$24.3 million
Boston Medical Center
$13.1 million
Massachusetts Institute of Technology
$9.7 million
Brandeis University
$6.5 million
Northeastern University
$6 million
Whitehead Institute for Biomedical Research
$5.6 million
Fenway Health
$4.4 million
The Forsyth Institute
$4.1 million
Harvard Pilgrim Health Care, Inc.
$3.9 million
University of Massachusetts Amherst
$2.9 million
Novartis Vaccines Institute for Global Health
$2.2 million
The Home for Little Wanderers including Boston Children's Services
$1.7 million
Worcester Polytechnic Institute
$1.2 million
Boston Biomedical Research Institute
$731 thousand
Boston College
$532 thousand
Clark University
$394 thousand
Howard M. Shapiro
$331 thousand
University of Massachusetts Boston
$300 thousand
Massachusetts industry in global health R&D

Massachusetts industry in global health R&D

AbbVie
Location(s): Worcester
Affinivax
Location(s): Cambridge
Alere
Location(s): Waltham
Amgen
Location(s): Cambridge, Woburn
Astellas
Location(s): Cambridge, Marlborough
AstraZeneca
Location(s): Waltham
Bristol-Myers Squibb
Location(s): Cambridge, Devens, Waltham
Celgene
Location(s): Cambridge
Charles River Laboratories
Location(s): Shrewsburg, Wilmington, Woburn, Worcester
Disease Diagnostic Group
Location(s): Cambridge
Eli Lilly and Company
Location(s): Cambridge
EMD Serono
Location(s): Billerica, Rockland
Genocea Biosciences
Location(s): Cambridge
GSK
Location(s): Cambridge
Merck & Co
Location(s): Boston
Microbiotix
Location(s): Worcester
Location(s): Cambridge
Novartis
Location(s): Cambridge
Oxford Immunotec
Location(s): Boston, Marlborough, Norwood
Pfizer
Location(s): Andover, Cambridge
Quidel
Location(s): Beverly
Quigen
Location(s): Waltham, Mansfield
Sanofi
Location(s): Allston, Cambridge, Framingham, Northborough, Waltham
Sarepta Therapeutics
Location(s): Andover, Cambridge
Transgene
Location(s): Cambridge

Massachusetts's top areas of global health R&D by USG funding

38.7%
HIV/AIDS
6.5%
Malaria
25.8%
Tuberculosis
12.3%
Diarrheal diseases
1.8%
Bacterial pneumonia & meningitis
10.1%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
Trachoma
4.7%
Other
Ebola/viral hemorrhagic fevers
Hepatitis C
Salmonella infections
Global health R&D at work in Massachusetts

Researchers from Harvard Medical School, Partners In Health, and Boston Children’s Hospital have shown that a new commercially developed rapid test for Ebola, performed at the point of care, was as effective as a conventional laboratory-based method. The successful field trial is a potential gamechanger. A test that can accurately diagnose Ebola within minutes provides clinicians with crucial information for treating patients and containing outbreaks.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: USAID